DE69616803T2 - Pharmazeutische zusammensetzung enthaltend interferon-gamma inhibitoren - Google Patents

Pharmazeutische zusammensetzung enthaltend interferon-gamma inhibitoren

Info

Publication number
DE69616803T2
DE69616803T2 DE69616803T DE69616803T DE69616803T2 DE 69616803 T2 DE69616803 T2 DE 69616803T2 DE 69616803 T DE69616803 T DE 69616803T DE 69616803 T DE69616803 T DE 69616803T DE 69616803 T2 DE69616803 T2 DE 69616803T2
Authority
DE
Germany
Prior art keywords
ifn
inhibitor
wounds
healing
injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69616803T
Other languages
German (de)
English (en)
Other versions
DE69616803D1 (de
Inventor
William Ferguson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Renovo Ltd
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovo Ltd filed Critical Renovo Ltd
Publication of DE69616803D1 publication Critical patent/DE69616803D1/de
Application granted granted Critical
Publication of DE69616803T2 publication Critical patent/DE69616803T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
DE69616803T 1995-08-18 1996-08-09 Pharmazeutische zusammensetzung enthaltend interferon-gamma inhibitoren Expired - Lifetime DE69616803T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9516967A GB2304342A (en) 1995-08-18 1995-08-18 Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma
PCT/GB1996/001949 WO1997007136A2 (en) 1995-08-18 1996-08-09 Pharmaceutical composition containing inhibitors of interferon-gamma

Publications (2)

Publication Number Publication Date
DE69616803D1 DE69616803D1 (de) 2001-12-13
DE69616803T2 true DE69616803T2 (de) 2002-06-20

Family

ID=10779448

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69616803T Expired - Lifetime DE69616803T2 (de) 1995-08-18 1996-08-09 Pharmazeutische zusammensetzung enthaltend interferon-gamma inhibitoren
DE69626050T Expired - Lifetime DE69626050T2 (de) 1995-08-18 1996-08-09 Pharmazeutische zusammensetzung enthaltend interferon-gamma stimulatoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69626050T Expired - Lifetime DE69626050T2 (de) 1995-08-18 1996-08-09 Pharmazeutische zusammensetzung enthaltend interferon-gamma stimulatoren

Country Status (12)

Country Link
EP (2) EP0972521B1 (enExample)
JP (2) JP4070809B2 (enExample)
AT (2) ATE231728T1 (enExample)
AU (1) AU713809B2 (enExample)
CA (1) CA2229590C (enExample)
DE (2) DE69616803T2 (enExample)
DK (2) DK0972521T3 (enExample)
ES (2) ES2192018T3 (enExample)
GB (1) GB2304342A (enExample)
PT (2) PT845007E (enExample)
WO (1) WO1997007136A2 (enExample)
ZA (1) ZA966953B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DK1137766T3 (da) 1998-12-09 2006-01-30 Protein Design Labs Inc Anvendelse af IL-12-antistoffer til behandling af psoriasis
EP1180037A2 (en) * 1999-05-26 2002-02-20 The Brigham and Women's Hospital Therapeutic uses of agents that modulate the activity of alpha-smooth muscle actin
US6710025B1 (en) 1999-05-26 2004-03-23 The Brigham And Women's Hospital, Inc. Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin
US10080779B2 (en) 2004-12-15 2018-09-25 Universite D'angers Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM
JP5530635B2 (ja) * 2007-02-14 2014-06-25 独立行政法人科学技術振興機構 腸管癒着抑制剤
GB0724231D0 (en) * 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
RU2539383C1 (ru) * 2013-11-29 2015-01-20 Закрытое акционерное общество "ФИРН М" (ЗАО "ФИРН М") Фармацевтическая композиция для лечения трофических язв и длительно незаживающих ран различной этиологии в виде мази

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78444A (en) * 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
EP0311616B1 (en) * 1986-06-17 1991-09-25 Biogen, Inc. Combinations of gamma interferons and anti-inflammatory or anti-pyretic agents for treating diseases
NL8700927A (nl) * 1987-04-16 1988-11-16 Stichting Rega V Z W Anti-interferon-gamma-antilichamen; en hun therapeutische toepassing.
CA1335792C (en) * 1987-08-18 1995-06-06 Chaim O. Jacob Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders
IL88378A (en) * 1988-11-14 2000-11-21 Yeda Res & Dev Human interferon-gamma binding proteins their manufacture and pharmaceutical compositions comprising them
ATE147634T1 (de) * 1988-12-19 1997-02-15 American Cyanamid Co Produkte zur behandlung des endotoxin -schocks bei einem säugetier
GB8905400D0 (en) * 1989-03-09 1989-04-19 Jonker Margreet Medicaments
DK0393502T3 (da) * 1989-04-19 1996-03-04 Hoffmann La Roche Opløselige interferon-gamma-receptorer og fremgangsmåder til fremstilling heraf
IT1231727B (it) * 1989-08-11 1991-12-21 Enrico Savoldi Peptidi utili per la determinazione e la purificazione di anticorpi anti gamma interferone.
IL91562A0 (en) * 1989-09-07 1990-04-29 Yeda Res & Dev Interferon-gamma receptor fragment and its production
ZA917669B (en) * 1990-09-27 1992-08-26 Schering Corp Antagonists of human gamma interferon
JPH05506673A (ja) * 1991-02-22 1993-09-30 アムジエン・インコーポレーテツド 迅速な創傷の治癒を促進するためのｇｍ―ｃｓｆ及びｇ―ｃｓｆの使用
NL9101290A (nl) * 1991-07-23 1993-02-16 Stichting Rega V Z W Recombinant dna-molecuul voor de expressie van een fv-fragment van een antilichaam.
DE4234380A1 (de) * 1992-10-06 1994-04-07 Schering Ag Verwendung von Dopaminagonisten zur Aktivierung des gamma-Interferon-Produktion
AU5669694A (en) * 1992-11-20 1994-06-22 Schering Corporation Antagonists of human gamma interferon
CA2148907C (en) * 1992-12-29 2008-07-08 Rebecca H. R. Ward Treatment of inflammatory bowel disease with ifn-gamma inhibitors
JPH09506263A (ja) * 1993-12-09 1997-06-24 アゲット，ミヒェル ＩＦＮ−γレセプターβ−鎖およびその誘導体

Also Published As

Publication number Publication date
JPH11511160A (ja) 1999-09-28
PT845007E (pt) 2002-03-28
GB2304342A (en) 1997-03-19
PT972521E (pt) 2003-06-30
JP4616291B2 (ja) 2011-01-19
ES2192018T3 (es) 2003-09-16
ATE231728T1 (de) 2003-02-15
EP0845007A2 (en) 1998-06-03
WO1997007136A3 (en) 1997-08-21
EP0972521B1 (en) 2003-01-29
ES2164911T3 (es) 2002-03-01
AU6707196A (en) 1997-03-12
JP4070809B2 (ja) 2008-04-02
GB9516967D0 (en) 1995-10-18
AU713809B2 (en) 1999-12-09
CA2229590C (en) 2010-10-12
DE69626050T2 (de) 2004-01-22
EP0972521A1 (en) 2000-01-19
DE69626050D1 (de) 2003-03-06
JP2007119497A (ja) 2007-05-17
DK0845007T3 (da) 2001-12-17
EP0845007B1 (en) 2001-11-07
CA2229590A1 (en) 1997-02-27
DE69616803D1 (de) 2001-12-13
DK0972521T3 (da) 2003-05-05
ATE208402T1 (de) 2001-11-15
HK1023516A1 (en) 2000-09-15
WO1997007136A2 (en) 1997-02-27
ZA966953B (en) 1998-02-16

Similar Documents

Publication Publication Date Title
DE69625516T2 (de) Verwendung von il-10 zur wundheilung mit verminderter narbenbildung
DE69312077T2 (de) Behandlung von autoimmun- und entzundungskrankheiten
DE69101316T2 (de) Empfänglichmachen von säugetieren für beschleunigte gewebereparatur.
DE69228556T2 (de) CDw52-SPEZIFISCHER ANTIKÖRPER ZUR BEHANDLUNG VON MULTIPLER SKLEROSE
DE69233643T2 (de) Verwendung von Antizytokin-enthaltenden pharmazeutischen Zusammensetzungen zur Therapie von multipler Sklerose
DE69713485T2 (de) Medikamente für die Behandlung oder Vorbeugung von Thrombocytopenie
DE69521536T2 (de) Zusammensetzungen die G-CSF und ein TNF-Bindungsprotein enthalten
DE68908431T2 (de) Methode zur Verminderung der Immunglobulin-E-Reaktion.
EP0346501B1 (de) Arzneimittelzubereitung zur behandlung des immunmangels
JP4616291B2 (ja) インターフェロン−ガンマスティミュレーター含有医薬組成物
US7220413B2 (en) Pharmaceutical composition containing inhibitors of interferon-γ
DE69634905T2 (de) Phosphnatanaloge von Mannose-6-phosphate und deren Verwendung zur Förderung der Heilung von Wunden oder fibrotischen Störungen mit verminderter Narbenbildung
DE69006221T2 (de) Verfahren zur behandlung von septischem schock.
DE69122960T3 (de) Verfahren und zubereitungen für die behandlung von verletzungen
US7727520B2 (en) Method of promoting the healing of a chronic wound
DE69333537T2 (de) T-peptid und damit verwandte Peptide in der Behandlung von entzündungen einschlies slich der Multiplen Sklerose
EP0343480A1 (de) Verwendung von Interleukin-2 zur Immunrekonstitution bei abgeschwächter Immunreaktion
DE69215568T2 (de) Verfahren zur Hemmung der Sauerstofftoxizität in den Lungen
EP1528922B1 (de) Verwendung von treosulfan und derivaten davon zur behandlung der multiplen sklerose
DE60019921T2 (de) Verwendung von interleukin-11 zur behandlung von hämoragischem schock
AU747598B2 (en) Pharmaceutical composition containing stimulators of interferon-gamma
DE19823351A1 (de) Mittel zur Verhinderung der Zellapoptose bei Krankheiten
DE60002143T2 (de) Behandlung autoimmunerkrankungen in säugern
HK1023516B (en) Pharmaceutical composition containing stimulators of interferon-gamma
CA2614655A1 (en) Pharmaceutical composition containing inhibitors of interferon-gamma

Legal Events

Date Code Title Description
8364 No opposition during term of opposition